International Stem Cell Corp
International Stem Cell Corporation, a clinical stage biotechnology company, focuses on the development of therapeutic and biomedical products in the United States, Asia, Europe, and internationally. It develops ISC-hpNSC, a neural stem cell program that has completed the Phase I clinical trial for the treatment of Parkinson's disease, as well as for treating stroke, traumatic brain injury, and A… Read more
Market Cap & Net Worth: International Stem Cell Corp (ISCO)
International Stem Cell Corp (OTCQB:ISCO) has a market capitalization of $960.53K ($960.53K) as of March 19, 2026. Listed on the OTCQB stock exchange, this USA-based company holds position #37740 globally and #12294 in its home market, demonstrating a 9.09% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying International Stem Cell Corp's stock price $0.12 by its total outstanding shares 8004389 (8.00 Million).
International Stem Cell Corp Market Cap History: 2015 to 2025
International Stem Cell Corp's market capitalization history from 2015 to 2025. Data shows change from $26.41 Million to $960.53K (-33.49% CAGR).
International Stem Cell Corp Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how International Stem Cell Corp's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.08x
International Stem Cell Corp's market cap is 0.08 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $26.41 Million | $7.55 Million | -$2.63 Million | 3.50x | N/A |
| 2016 | $8.24 Million | $7.17 Million | -$1.08 Million | 1.15x | N/A |
| 2017 | $12.81 Million | $7.46 Million | -$6.07 Million | 1.72x | N/A |
| 2018 | $12.25 Million | $11.09 Million | -$2.13 Million | 1.10x | N/A |
| 2019 | $4.64 Million | $9.47 Million | -$4.26 Million | 0.49x | N/A |
| 2020 | $2.96 Million | $7.13 Million | -$2.72 Million | 0.42x | N/A |
| 2021 | $3.76 Million | $7.18 Million | -$899.00K | 0.52x | N/A |
| 2022 | $1.44 Million | $8.18 Million | -$331.00K | 0.18x | N/A |
| 2023 | $480.26K | $7.79 Million | -$131.00K | 0.06x | N/A |
| 2024 | $720.40K | $9.09 Million | -$209.00K | 0.08x | N/A |
Competitor Companies of ISCO by Market Capitalization
Companies near International Stem Cell Corp in the global market cap rankings as of March 19, 2026.
Key companies related to International Stem Cell Corp by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
International Stem Cell Corp Historical Marketcap From 2015 to 2025
Between 2015 and today, International Stem Cell Corp's market cap moved from $26.41 Million to $ 960.53K, with a yearly change of -33.49%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $960.53K | +33.33% |
| 2024 | $720.40K | +50.00% |
| 2023 | $480.26K | -66.67% |
| 2022 | $1.44 Million | -61.70% |
| 2021 | $3.76 Million | +27.03% |
| 2020 | $2.96 Million | -36.21% |
| 2019 | $4.64 Million | -62.09% |
| 2018 | $12.25 Million | -4.38% |
| 2017 | $12.81 Million | +55.34% |
| 2016 | $8.24 Million | -68.79% |
| 2015 | $26.41 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of International Stem Cell Corp was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $960.53K USD |
| MoneyControl | $960.53K USD |
| MarketWatch | $960.53K USD |
| marketcap.company | $960.53K USD |
| Reuters | $960.53K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.